FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2282-2284 May 25, 2006 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Tyrosine kinases are major targets of contemporary chemotherapy, and tyrosine kinase inhibitors — such as imatinib mesylate (Gleevec, Novartis; formerly known as STI571) — are approved for the treatment of some forms of chronic myelogenous leukemia and a rare form of stomach cancer called gastrointestinal stromal tumor. Surprisingly, some types of gastrointestinal stromal tumors refractory to the antiproliferative effects of imatinib mesylate in vitro were shown recently to respond to the drug in vivo, with the response dependent on immune-cell function.¹ One group of investigators following up on this finding in greater depth² and another independently assessing innate immune cells³ . . . [Full Text of this Article]

Source Information

From the Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

This article has been cited by other articles:

• Mignot, G., Ullrich, E., Bonmort, M., Menard, C., Apetoh, L., Taieb, J., Bosisio, D., Sozzani, S., Ferrantini, M., Schmitz, J., Mack, M., Ryffel, B., Bulfone-Paus, S., Zitvogel, L., Chaput, N. (2008). The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2. J. Immunol. 180: 6477-6483 [Abstract] [Full Text]  
• Carpenter, P. A., Snyder, D. S., Flowers, M. E. D., Sanders, J. E., Gooley, T. A., Martin, P. J., Appelbaum, F. R., Radich, J. P. (2007). Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109: 2791-2793 [Abstract] [Full Text]  
• Perros, F., Dorfmuller, P., Souza, R., Durand-Gasselin, I., Mussot, S., Mazmanian, M., Herve, P., Emilie, D., Simonneau, G., Humbert, M. (2007). Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 29: 462-468 [Abstract] [Full Text]